Your SlideShare is downloading. ×
Global Renal Denervation Market
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Global Renal Denervation Market

1,059
views

Published on

Published in: Health & Medicine, Business

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,059
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. View Report Details Global Renal Denervation Market------------------------------------------------- 2012
  • 2. View Report DetailsExecutive SummaryAffecting the lives of millions of people across the globe, hypertension is a chronic medical condition which substantiallyraises the risk of cardiac malfunction, kidney diseases and insulin resistance. However if the condition is tamed bymanaging the blood pressure, it suppresses the risk of occurrence of adverse events significantly. But when not treatedtimely, it increases the risk of mortality from ischemic heart disease and stroke two folds.Renal artery denervation (RDN) is a novel therapeutic paradigm meant for treating the resistant hypertension. Basically,RDN is a catheter-based therapy which employs either radiofrequency or ultrasound energy for tampering the renalarteries sympathetic nerves whose hyperactivity causes treatment-resistant hypertension.RDN devices and technologies are the most sought after innovations in the field of medical technology as they provide foran approach for managing and controlling the resistant hypertension, something that wasn’t available in the paramedics’field before.Developing novel medical devices using technologies which employ high frequency radiations has been a widely acceptedtrend these days. The companies operating in this field have been manufacturing devices which are used in the diagnosisand treatment of numerous medical conditions like cancer and hypertension. Despite being a technology which principallyworks using radiations for medical therapy, RDN has been proven minimally invasive and efficient when practicedheedfully.The ongoing trends in the respective market include Medtronic’s HTN-3 pivotal study, development of novel renaldenervation devices, devising of baroreceptor stimulation technology, ongoing clinical trials and techniques to address theexisting limitations of the current technologies. The drivers promoting RDN market’s growth incorporate factors likeincreasing cases of hypertension, increasing expenditure on healthcare, rising adult population worldwide, and increasingglobal GNI. Although it’s been a new development in the field of paramedics, it has its own share of difficulties and hurdleswhere situations and elements such as limitations of invasive technology and treatment-resistant hypertension have beenposing acute challenges. The leading players dominating RDN market space include Medtronic Inc., Boston ScientificCorp., St. Jude Medical Inc. and Covidien.This RDN Market report attempts to elicit the rapidly evolving market by scrutinizing the novel technologies, productofferings, top notch industry players and their respective market shares.
  • 3. Global Renal Denervation Market : Overview Global Interventional Hypertension Procedures (2011-2015E)  The estimated size of the interventional hypertension treatment market is expected to reach somewhere around US$..........million by 2015 in the US and developed Europe and is projected to be US$........billion by 2020.……………  In 2011, the number of interventional hypertension procedures was …… and are expected to rise by ………….% reaching ……….. in 2012.…………….  In the US, hypertension cases have been rising at a significant rate, which is evident by the fact that the number of cases as a percentage of adult population increased from …….% in 2010 to ………….% in 2011……………  In 2010, the number of patients suffering with hypertension as a percentage of total adult population in the Europe was ……..%, which increased to ……….% in 2011. However the number of patients treated for hypertension as a Hypertension Prevalence in the US (2010-2015E) percentage of total hypertension patients has also been on a rise. ……………….  The key competitors of the industry include Boston Scientific, Covedien and St. Jude.……………..
  • 4. Renal Denervation in Various Regions Hypertension Prevalence in the Developed Europe (2010-2015E)  Europe accounts for the largest share of the global renal denervation market, in terms of procedure, with approximately …..% or ……. RDN procedures as of 2011.  The next major contributor is the US with …….RDN procedures, or around ……..%, of the global market for RDN procedures. The remaining ………….. procedures were performed in the rest of the world during the year. ……………………..  In terms of revenues, as of 2011 the staggering share worth US$...........million (……%) was accounted by Europe, followed by the US with US$....... million revenues, thereby constituting approximately …………….% of the global RDN market revenues.…………………. Worldwide RDN Revenue Share by Region (2011) Worldwide RDN Procedure Share by Region (2011) )
  • 5. Global RDN Market Growth Global RDN Market Growth (2011-2015E) Worldwide RDN Revenue Share by Geography (2012E and 2020E)  The global renal denervation market is projected to grow at a CAGR of ………% over a period of 4 years from US$..... million 2011 to US$........ million in 2015.  In terms of revenue generation in the RDN market, the region expected to be claim the top spot for the year 2012 is Europe, with an estimated revenue share worth ….%. However, this share is expected to come down to …….% by 2020 as it is likely to be taken over by other geographies like Japan, the US, and other countries.  Key Trends include: Medtronic’s HTN-3 pivotal study, development of novel renal denervation devices, devising of baroreceptor stimulation technology , ongoing clinical trials and addressing the existing limitations of the current technologies.  Growth Drivers include: increasing cases of hypertension, increasing expenditure on healthcare, rising adult population , worldwide and increasing global GNI (gross national income) .  Challenges include: limitations of invasive technology for treatment and treatment-resistant hypertension …………………………. Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
  • 6. View Report DetailsTable of Contents Tables and Charts1. Hypertension List of Charts1.1 Overview BP Pattern across various Stages of HypertensionBP Pattern Global Interventional Hypertension Procedures (2011-2015E)Essential Hypertension Hypertension Prevalence in the US (2010-2015E)Treatment Options Hypertension Prevalence in the Developed Europe (2010-2015E) RDN Device Comparison – 30-Day BP Change1.2 Global Hypertension Market Worldwide RDN Procedure Share by Region (2011) Worldwide RDN Revenue Share by Region (2011)Market Overview Rising Global Adult Population (2007-2012E)Procedure Growth World Gross National Income (2005-2010)Market Share Medtronic’s Revenue Share by Business Segments (2012) Medtronic’s Revenue and Net Earnings Analysis (2009-2012)1.3 The US Hypertension Market St. Jude Medical’s Revenue Share by Business Segments (2011) St. Jude Medical’s Revenue and Net Earnings Analysis (2007-2011)Hypertension Prevalence Boston Scientific’s Revenue Share by Business Segments (2011)Market Opportunity Boston Scientific’s Revenue and Net Income Analysis (2007-2011) Covidien’s Revenue Share by Business Segments (2011)1.4 European Hypertension Market Covidien’s Revenues and Net Income Analysis (2007-2011) Worldwide RDN Procedure Share by Geography (2012E andHypertension Prevalence 2020E)Market Opportunity Worldwide RDN Revenue Share by Geography (2012E and 2020E) Global RDN Market Growth (2011-2015E)2. Renal Denervation2.1 OverviewRDN Device ComparisonRDN Application beyond Hypertension2.2 Renal Denervation MarketGlobal MarketEuropeUnited StatesRest of World
  • 7. View Report Details3. Renal Denervation - Market Dynamics Tables and Charts3.1 Key Trends List of Tables3.1.1 Medtronic’s HTN-3 Pivotal Study Classes of Essential Hypertension3.1.2 Development of Novel Renal Denervation Devices Global Interventional Hypertension Market Model3.1.3 Devising of Baroreceptor Stimulation Technology Patients Taking = 5 Hypertension Medications (2010)3.1.4 Ongoing Clinical Trials U.S. Interventional Hypertension Unit Build (2010-2015E)3.1.5 Addressing the Existing Limitations of the Current Developed Europe Interventional Hypertension Unit BuildTechnologies Interventional Hypertension Treatment Products in Development Global Renal Denervation Market (2011)3.2 Growth Drivers European Renal Denervation Market (2011) US Renal Denervation Market (2011)3.2.1 Increasing Cases of Hypertension Rest of the World Renal Denervation Market (2011)3.2.2 Increasing Expenditure on Healthcare Clinical Trials for Competitive Technologies3.2.3 Rising Adult Population Worldwide Renal Denervation Programs3.2.4 Increasing Global GNI (Gross National Income) Renal Denervation Technologies Renal Denervation Competitive Technologies Under Development3.3 Challenges Global RDN Procedures and Revenue Forecast (2012E-2020E) Europe RDN Procedures and Revenue Forecast (2012E-2020E)3.3.1 Limitations of Invasive Technology for Treatment The US RDN Procedures and Revenue Forecast (2012E-2020E)3.3.2 Treatment-resistant Hypertension Japan RDN Procedures and Revenue Forecast (2014E-2020E) Rest of the World RDN Procedures and Revenue Forecast4. Renal Denervation - Competitive Landscape (2012E-2020E)Competitive OverviewRenal Denervation ProgramsTechnology Comparison5. Company Profiles5.1 MedtronicBusiness OverviewFinancial OverviewBusiness StrategiesExpanding Market Share/Product PortfolioMarketing and Distribution Tactics
  • 8. View Report Details5.2 St. Jude MedicalBusiness OverviewFinancial OverviewBusiness StrategiesInnovative Device FabricationPortfolio Expansion through Acquisitions5.3 Boston ScientificBusiness OverviewFinancial OverviewBusiness StrategiesFocus on Research & DevelopmentImproving Financial Flexibility5.4 CovidienBusiness OverviewFinancial OverviewBusiness StrategiesEmphasis on InnovationFocus on Operational Excellence6. RDN Market OutlookGlobal MarketEuropeUnited StatesRest of World
  • 9. View Report Details Contact Us:These are abridged and sanitized sample pages from the comprehensive report on the “Global Renal Denervation Market”. Toknow more about this report or for any customized research requirement, please contact the following: Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 Vikas Gupta T. +91-120-4130959 BD Manager C: +91-9811715635 vikas@konceptanalytics.com www.konceptanalytics.com